| Q48581499 | 3-O-methyl metabolites of catecholamines: Automated fluorometric assay and their plasma levels in patients receiving levodopa and carbidopa |
| Q40907035 | A double-blind comparison of levodopa, madopa, and sinemet in Parkinson disease |
| Q92461375 | A novel pathway for microbial metabolism of levodopa |
| Q43521470 | Bromocriptine lessens the incidence of mortality in L-dopa-treated parkinsonian patients: prado-study discontinued |
| Q68647751 | Catecholamines--a symposium |
| Q57088811 | Clinical pharmacology and therapeutic use of COMT inhibition in Parkinson's disease |
| Q67215110 | Drug-Induced Movement Disorders |
| Q48698393 | Effect of dopamine, l-dopa, carbidopa and l-dopa/carbidopa on arthus and delayed hypersensitivity skin reactions in the rat |
| Q39297353 | Failure of pyridoxine to affect neuroleptic-induced hyperprolactinemia in psychotic patients |
| Q38285461 | Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr |
| Q43190922 | In vivo effects of new inhibitors of catechol-O-methyl transferase |
| Q71036806 | Intestinal absorption of levodopa in man |
| Q34075760 | L-Dopa and the Treatment of Extrapyramidal Disease |
| Q53729853 | L-alpha-methyldopa hydrazine (Carbidopa) combined with L-dopa in the treatment of Parkinson's disease. |
| Q39628159 | Lack of Acute Effects of Pyridoxine on Prolactin Secretion and Lactation |
| Q40575022 | Levodopa and decarboxylase inhibitors: a review of their clinical pharmacology and use in the treatment of parkinsonism |
| Q38684994 | Levodopa in Parkinson's disease: current status and future Developments |
| Q33770264 | Levodopa in Parkinson's disease: neurotoxicity issue laid to rest? |
| Q47948932 | Levodopa: A new look at an old friend |
| Q37451831 | Monoamine oxidase and cerebral uptake of dopaminergic drugs |
| Q38374505 | Mucuna pruriens in Parkinson disease: A double-blind, randomized, controlled, crossover study |
| Q35217260 | Neuropharmacology of dopamine receptors:: Implications in neuropsychiatric diseases |
| Q40577673 | Orthostatic stability with intravenous levodopa |
| Q48588603 | Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson's disease |
| Q23913771 | Protein Intake and Treatment of Parkinson's Disease with Levodopa |
| Q48443695 | Sequential analysis: manganese, catecholamines and L-dopa induced dyskinesia |
| Q37925513 | Striatal Signaling in L-DOPA-Induced Dyskinesia: Common Mechanisms with Drug Abuse and Long Term Memory Involving D1 Dopamine Receptor Stimulation. |
| Q48475595 | Stronger Dopamine D1 Receptor-Mediated Neurotransmission in Dyskinesia |
| Q37896026 | The Interactions between Vitamin B6 and Hormones |
| Q39227738 | The effects of a decarboxylase inhibitor, benserazide, on both thermoregulation and chlorpromazine-induced hypothermia in rats |
| Q22252881 | The history of dopamine and levodopa in the treatment of Parkinson's disease |
| Q40214837 | The pharmacology of Parkinson's disease: basic aspects and recent advances |